$Apellis制药(APLS)$ 药物开卖的第二个完整季度，中间还爆出了retinal vasculitis，只是短暂影响了销售，预计第三季度卖74M，真不错呀
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in August